Hemodynamic Effects of Sacubitril/Valsartan in Patients with Reduced Left Ventricular Ejection Fraction Over 24 Months: A Retrospective Study

被引:11
作者
Abumayyaleh, Mohammad [1 ,2 ,3 ]
Demmer, Jonathan [1 ]
Krack, Carina [1 ]
Pilsinger, Christina [1 ]
El-Battrawy, Ibrahim [1 ,2 ,3 ]
Behnes, Michael [1 ]
Aweimer, Assem [4 ]
Muegge, Andreas [4 ]
Lang, Siegfried [1 ,2 ,3 ]
Akin, Ibrahim [1 ,2 ,3 ]
机构
[1] Heidelberg Univ, Univ Med Ctr Mannheim, Med Fac Mannheim, Dept Cardiol Angiol Haemostaseol & Med Intens Car, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany
[2] European Ctr AngioSci ECAS, Mannheim, Germany
[3] DZHK German Ctr Cardiovasc Res DZHK, Partner Site, Mannheim, Germany
[4] Ruhr Univ Bochum, Bergmannsheil Univ Hosp, Dept Cardiol & Angiol, Bochum, Germany
关键词
HEART-FAILURE; NEPRILYSIN INHIBITION;
D O I
10.1007/s40256-022-00525-w
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The effects of sacubitril/valsartan in patients with chronic heart failure with reduced ejection fraction (HFrEF) were recently reported. However, the hemodynamic impact of this well-established treatment in patients with HFrEF has been poorly systematically researched. Aim We aimed to investigate the hemodynamic effects of sacubitril/valsartan among patients with HFrEF. Methods Between 2016 and 2020, we retrospectively collected data for patients with HFrEF treated at the University Medical Center Mannheim, Germany. Data for 240 patients with HFrEF were available. We systematically analyzed echocardiographic parameters, all-cause hospitalization, and congestion rate. Results The left ventricular ejection fraction (LVEF) improved from a median (minimum; maximum) of 28% (3; 65) before initiation of sacubitril/valsartan to a median of 34% (13; 64) at 24-month follow-up (p < 0.001). Systolic pulmonary atrial pressure (PAPsys) decreased from a median of 30 mmHg (13; 115) to 25 mmHg (20; 80) at 24-month follow-up (p = 0.005). The median (minimum; maximum) tricuspid annular plane systolic excursion improved from 17 mm (3; 31) at baseline to 20 mm (9; 30) at 12-month follow-up (p = 0.007). The incidence of severe and moderate mitral, tricuspid, and aortic valvular insufficiency improved after treatment. Hospitalization and congestion rates reduced at 24-month follow-up. The mortality rate in echocardiographic and functional nonresponders was higher than in responders (12.1 vs. 5.2%; p = 0.1 and 11.3 vs. 3.1%; p = 0.01, respectively). Conclusion Follow-up 24 months after starting treatment with sacubitril/valsartan revealed sustained improvements in echocardiographic parameters, including LVEF, PAPsys, and cardiac valvular insufficiency. Rates of all-cause hospitalization and congestion had decreased significantly at follow-up. The mortality rate was higher in echocardiographic and functional nonresponders.
引用
收藏
页码:535 / 544
页数:10
相关论文
共 18 条
  • [1] Almufleh A, 2017, AM J CARDIOVASC DIS, V7, P108
  • [2] Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists
    Ambrosy, Andrew P.
    Braunwald, Eugene
    Morrow, David A.
    DeVore, Adam D.
    McCague, Kevin
    Meng, Xiangyi
    Duffy, Carol I.
    Rocha, Ricardo
    Velazquez, Eric J.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 76 (09) : 1034 - 1048
  • [3] Medication Adherence: WHO Cares?
    Brown, Marie T.
    Bussell, Jennifer K.
    [J]. MAYO CLINIC PROCEEDINGS, 2011, 86 (04) : 304 - 314
  • [4] High-risk percutaneous coronary intervention is associated with reverse left ventricular remodeling and improved outcomes in patients with coronary artery disease and reduced ejection fraction
    Daubert, Melissa A.
    Massaro, Joseph
    Liao, Lawrence
    Pershad, Ashish
    Mulukutla, Suresh
    Ohman, Erik Magnus
    Popma, Jeffrey
    O'Neill, William W.
    Douglas, Pamela S.
    [J]. AMERICAN HEART JOURNAL, 2015, 170 (03) : 550 - 558
  • [5] Effectiveness of self-management interventions on mortality, hospital readmissions, chronic heart failure hospitalization rate and quality of life in patients with chronic heart failure: A systematic review
    Ditewig, Joanne B.
    Blok, Helene
    Havers, Jeroen
    van Veenendaal, Haske
    [J]. PATIENT EDUCATION AND COUNSELING, 2010, 78 (03) : 297 - 315
  • [6] Persistent Use of Secondary Preventive Drugs Declines Rapidly During the First 2 Years After Stroke
    Glader, Eva-Lotta
    Sjolander, Maria
    Eriksson, Marie
    Lundberg, Michael
    [J]. STROKE, 2010, 41 (02) : 397 - 401
  • [7] Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction
    Januzzi, James L., Jr.
    Prescott, Margaret F.
    Butler, Javed
    Felker, G. Michael
    Maisel, Alan S.
    McCague, Kevin
    Camacho, Alexander
    Pina, Lleana L.
    Rocha, Ricardo A.
    Shah, Amil M.
    Williamson, Kristin M.
    Solomon, Scott D.
    Aslam, Ahmad
    Vora, Kishor
    Desai, Sunil
    Foucauld, Jean
    Modi, Mayank
    Wang, David
    Berk, Martin
    Martinez-Castrilon, Melvin
    Kraus, David
    Grena, Paul
    Sanchez, Eulogio
    Lloret, Ramon
    Aggarwala, Gaurav
    Anglade, Moise
    Eaves, William
    Gianfagna, Robert
    Schwartz, Michael
    Joshi, Nikhil
    Galtes, Israel
    Somodevilla, Guillermo
    Jackson, Richard
    Lewis, Gregory
    Peters, Michael
    Lupovitch, Steven
    Phillips, Andrea
    Chhabra, Anil
    Perez, Guido
    Venugopal, Chandra
    Lyandres, Yuly
    King, Anthony
    Bradley, Arden
    Dakour, Ramzi
    Braden, Stephen
    Muneer, Basharat
    Bart, Bradley
    Kapadia, Shaival
    Shah, Neerav
    Nadar, Venkatesh
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2019, 322 (11): : 1085 - 1095
  • [8] Angiotensin Receptor Neprilysin Inhibitor for Functional Mitral Regurgitation PRIME Study
    Kang, Duk-Hyun
    Park, Sung-Ji
    Shin, Sung-Hee
    Hong, Geu-Ru
    Lee, Sahmin
    Kim, Min-Seok
    Yun, Sung-Cheol
    Song, Jong-Min
    Park, Seung-Woo
    Kim, Jae-Joong
    [J]. CIRCULATION, 2019, 139 (11) : 1354 - 1365
  • [9] Angiotensin Receptor-Neprilysin Inhibition Attenuates Right Ventricular Remodeling in Pulmonary Hypertension
    Kia, Danial Sharifi
    Benza, Evan
    Bachman, Timothy N.
    Tushak, Claire
    Kim, Kang
    Simon, Marc A.
    [J]. JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2020, 9 (13):
  • [10] The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction
    Martens, Pieter
    Belien, Hanne
    Dupont, Matthias
    Vandervoort, Pieter
    Mullens, Wilfried
    [J]. CARDIOVASCULAR THERAPEUTICS, 2018, 36 (04)